News
DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa® allowed patients to achieve
PSP Swiss Property kauft erstklassige Geschäftsliegenschaft in CBD-Genf
PSP Swiss Property buys prime property in CBD Geneva
Oerlikon Publishes Sustainability Report 2021
Oerlikon has published today its Sustainability Report 2021, outlining the progress and achievements of the company in environmental, social and governance topics.
This press release features
Publication of definitive end result for Vifor Pharma tender offer
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220327005085/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Helvetia increases volume, profits and dividend - Smile becomes European
Helvetia steigert Volumen, Gewinn und Dividende - Smile wird europäisch
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006149/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Dufry extends duty-free concession for six years and increases retail space at Bali International Airport
Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220307005938/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Dufry with strong recovery reporting Organic Growth of 53.2% and Adjusted Operating Profit of CHF 374.9 million
Hudson Expands Food & Beverage Portfolio With Starbucks
Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220302006217/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Neue Behandlungsoption für Patienten mit SHPT – Rayaldee® in der Schweiz ab sofort verfügbar
Vifor Pharma Schweiz AG gab heute die Markteinführung des Calcifediol-Retardpräparats Rayaldee® in der Schweiz bekannt. Rayaldee® ist die erste und einzige in Europa zugelassene orale Therapie
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220227005069/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Vifor Pharma reports sustained growth in 2021
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group reported a solid performance in 2021 and an increase in profitability, supported by a strong recovery in Ferinject
Vifor Pharma Gruppe erzielt nachhaltiges Wachstum in 2021
Regulatory News:
AD HOC-MITTEILUNG GEMÄSS ART. 53 KR
Die Vifor Pharma Gruppe verzeichnete 2021 eine solide Geschäftsentwicklung und eine Steigerung der Profitabilität, die von einer starken
Vifor Pharma gibt Markteinführung von Tavneos® in Deutschland bekannt
Vifor Pharma Deutschland GmbH hat heute die Markteinführung von Tavneos® bekannt gegeben, der ersten in Europa zugelassenen oralen Therapie für die Behandlung der beiden Haupttypen von
Invitation to Dufry's Full Year Results 2021 on March 8, 2022
Vifor Pharma appoints two new members to the Executive Committee
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma Group today announced the appointment of acting Chief Financial Officer Alexandros Sigalas and Group General Counsel Dr
VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Commission has approved Tavneos® in combination with a rituximab or cyclophosphamide regimen
CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005418/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with
Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005059/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor
